NBIX · Neurocrine Biosciences Inc

$180.79 -2.04 (-1.12%) At close · Jul 29 Earnings today

Market Cap

$18.18B

100.55M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kyle W. Gano	CEO	$920,000	$966,000	$5,750,023	$5,750,006	—	$62,906	$13,448,935
Sanjay Keswani	Chief Medical Officer	$379,167	$488,000	$4,000,120	$3,999,963	—	$140,553	$9,007,803
Jude Onyia	Director	$720,520	$645,000	$2,999,925	$3,000,011	—	$45,313	$7,410,769
Matthew C. Abernethy	CFO	$725,913	$526,000	$2,499,918	$2,500,036	—	$60,045	$6,311,912
Strategic Advisor	—	$731,400	$530,000	$2,375,004	$2,375,029	—	$61,599	$6,073,032
Eric Benevich	Chief Commercial Officer	$668,690	$463,000	$2,349,928	$2,349,995	—	$57,334	$5,888,947

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$779,357	$1,141,950	$7,000,139	$6,999,698	—	$97,493	$16,018,637
Kyle W. Gano	CEO	$698,217	$536,906	$3,700,106	$3,549,970	—	$50,223	$8,535,422
Jude Onyia	Director	$676,545	$505,717	$2,440,182	$3,359,848	—	$53,559	$7,035,851
Strategic Advisor	—	$686,761	$513,354	$2,350,087	$3,150,017	—	$64,099	$6,764,318
Eiry Roberts	Chief Medical Officer	$686,761	$513,354	$2,350,087	$3,150,017	—	$64,099	$6,764,318
Matthew C. Abernethy	CFO	$684,824	$452,840	$2,599,987	$2,799,904	—	$57,646	$6,595,201
Eric Benevich	Chief Commercial Officer	$636,848	$366,188	$2,800,081	$2,449,932	—	$53,115	$6,306,164

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$946,000	$1,040,600	$7,021,386	$6,678,790	—	$64,036	$15,750,812
Jude Onyia	Director	$638,250	$351,038	$2,625,124	$3,375,024	—	$233,780	$7,223,216
Matthew C. Abernethy	CFO	$646,061	$355,335	$1,812,563	$3,187,536	—	$56,387	$6,057,882
Kyle W. Gano	CEO	$602,912	$331,602	$1,812,563	$3,187,536	—	$55,602	$5,990,215
Eiry Roberts	Chief Medical Officer	$660,348	$399,511	$2,125,112	$2,625,024	—	$63,852	$5,873,847

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$860,000	$989,000	$5,125,079	$4,875,106	—	$53,342	$11,902,527
Eiry Roberts	Chief Medical Officer	$631,912	$345,182	$2,075,144	$2,625,057	—	$57,986	$5,735,281
Kyle W. Gano	CEO	$550,605	$332,428	$1,725,086	$2,775,053	—	$38,485	$5,421,657
Matthew C. Abernethy	CFO	$618,240	$373,262	$1,570,128	$2,310,061	—	$52,632	$4,924,323
Darin M. Lippoldt	Chief Legal Officer and Corporate Secretary	$548,730	$315,520	$1,550,136	$2,250,049	—	$56,761	$4,721,196
Jude Onyia	Director	$575,000	$330,625	$1,275,146	$225,008	—	$55,520	$2,461,299

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$825,000	$701,250	$6,406,366	$6,093,752	—	$55,044	$14,081,412
Jude Onyia	Director	$52,340	$26,170	$3,000,136	$4,500,035	—	$2,949	$7,581,630
Eiry Roberts	Chief Medical Officer	$604,700	$272,115	$2,875,113	$2,625,019	—	$48,649	$6,425,596
Matthew C. Abernethy	CFO	$588,800	$264,960	$2,375,068	$2,625,019	—	$53,003	$5,906,850
Kyle W. Gano	Chief Executive Officer and Director	$517,000	$271,425	$2,375,067	$2,625,018	—	$22,814	$5,811,324
Eric Benevich	Chief Commercial Officer	$534,900	$213,960	$2,375,068	$2,625,019	—	$56,139	$5,805,086
Darin M. Lippoldt	Chief Legal Officer and Corporate Secretary	$525,100	$262,550	$2,312,606	$2,437,544	—	$52,361	$5,590,161

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$775,000	$542,500	$5,375,188	$7,124,633	—	$63,311	$13,880,632
Kyle W. Gano	Chief Executive Officer and Director	$487,700	$207,273	$2,750,208	$3,750,008	—	$16,751	$7,211,940
Eric Benevich	Chief Commercial Officer	$499,900	$199,960	$3,000,257	$2,999,869	—	$48,974	$6,748,960
Matthew C. Abernethy	CFO	$545,200	$190,820	$2,500,266	$2,999,869	—	$45,021	$6,281,176
Eiry Roberts	Chief Medical Officer	$575,900	$215,963	$2,375,242	$2,624,855	—	$56,073	$5,848,033
Darin M. Lippoldt	Chief Legal Officer and Corporate Secretary	$486,200	$170,170	$2,312,780	$2,437,508	—	$45,704	$5,452,362

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$725,000	$667,000	$2,000,071	$6,000,525	—	$58,230	$9,450,826
Matthew C. Abernethy	CFO	$495,600	$284,970	$1,250,035	$3,750,345	—	$42,170	$5,823,120
Eric Benevich	Chief Commercial Officer	$467,200	$280,320	$1,250,035	$3,750,345	—	$45,547	$5,793,447
Eiry Roberts	Chief Medical Officer	$538,200	$309,465	$1,000,076	$3,000,285	—	$51,889	$4,899,915
Haig P. Bozigian	Chief Development Officer	$461,500	$265,363	$1,000,076	$3,000,285	—	$53,772	$4,780,996
Kyle W. Gano	Chief Executive Officer and Director	$443,400	$266,040	$1,000,076	$3,000,285	—	$16,171	$4,725,972

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$675,000	$425,250	$2,998,832	$4,486,852	—	$47,045	$8,632,979
Eiry Roberts	Chief Medical Officer	$490,700	$220,800	$4,053,869	$2,863,700	—	$671,554	$8,300,623
Kyle W. Gano	Chief Executive Officer and Director	$403,100	$191,473	$2,656,575	$1,309,024	—	$8,069	$4,568,241
Eric Benevich	Chief Commercial Officer	$432,600	$205,485	$1,499,417	$1,496,335	—	$38,768	$3,672,605
Haig P. Bozigian	Chief Development Officer	$439,500	$197,775	$1,003,685	$1,309,024	—	$43,822	$2,993,806
Matthew C. Abernethy	CFO	$420,000	$199,500	$1,996,506	—	—	$69,741	$2,685,747

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$640,000	$515,200	$1,426,920	$4,929,898	—	$44,356	$7,556,374
Matthew C. Abernethy	CFO	$38,231	$20,071	$920,000	$2,416,800	—	$394,190	$3,789,292
Eric Benevich	Chief Commercial Officer	$410,000	$246,000	$458,344	$1,825,536	—	$37,722	$2,977,602
Haig P. Bozigian	Chief Development Officer	$408,800	$235,060	$458,344	$1,825,536	—	$41,694	$2,969,434

Executive changes

Person	Role	Change	Effective	Filed
Johanna Mercier	Class III Director	Appointed	—	2026-05-28
Gary A. Lyons	Class III Director	Appointed	—	2026-05-28
Kevin C. Gorman, Ph.D.	Class III Director	Appointed	—	2026-05-28

Key facts CIK 914475 CUSIP 64125C109 13F (30d) 255 filings 228 filers Visit website Investor relations